Digital Breakthrough Targets Schizophrenia's Most Stubborn Symptoms as FDA Clears First Smartphone-Based Treatment

For the estimated 60% of people with schizophrenia who experience debilitating negative symptoms—including loss of motivation, inability to feel pleasure, and social withdrawal—treatment options have been virtually nonexistent. That landscape changed this week as the FDA granted 510(k) clearance to Click Therapeutics' Motivista (CT-155), marking the first prescription digital therapeutic specifically indicated for treating these persistent symptoms in adults with clinically stable schizophrenia.

Unlike antipsychotic medications that primarily address hallucinations and delusions, Motivista targets the negative symptoms that often persist even when positive symptoms are controlled. The smartphone-delivered application combines evidence-based psychosocial therapies with digital methods, requiring approximately one hour of patient engagement per week—comparable to conventional in-person psychotherapy but accessible through a mobile device.

Phase 3 Trial Demonstrates Significant Improvement

The FDA clearance was supported by results from the Phase 3 CONVOKE study, which demonstrated statistically significant improvement over a digital control. At the primary endpoint of Week 16, patients using Motivista showed a 6.8-point improvement on the CAINS-MAP scale, compared to a 4.2-point improvement in the digital control group.

The safety profile proved favorable, with no serious treatment-related adverse events reported during the trial. Adherence rates remained strong, with 70.4% of Motivista users maintaining consistent engagement through Week 15, compared to 76.5% for the digital control group. Click Therapeutics is conducting an open-label extension study to evaluate long-term engagement and durability of effect.

New Treatment Category for Underserved Need

Motivista is indicated for adults aged 18 and older with schizophrenia who have clinically stable positive symptoms, and is intended as an adjunct to antipsychotic therapy and outpatient care. The clearance establishes a new treatment category addressing symptoms—avolition, anhedonia, and social withdrawal—that have historically remained resistant to pharmacological intervention.

The 510(k) clearance pathway suggests Click Therapeutics established substantial equivalence to existing devices, potentially streamlining future competitive entries in this emerging market segment. For the digital therapeutics industry, the approval represents validation of smartphone-delivered psychosocial interventions for serious mental illness and may accelerate payer coverage frameworks for prescription digital therapeutics in psychiatry.

Commercial Rollout and Access

Click Therapeutics, a privately held developer of software-based prescription medical treatments, is working with payers, healthcare providers, and patient advocacy organizations to facilitate broader access to Motivista. The company's commercial success will likely hinge on reimbursement negotiations and integration into existing schizophrenia care pathways.

For healthcare providers, Motivista offers an evidence-based adjunctive option that requires minimal clinical oversight while addressing symptoms that significantly impact patients' quality of life and functional outcomes. The treatment's smartphone-based delivery model may also improve access for patients in underserved areas with limited availability of specialized psychosocial interventions.

Sources

1. FDA Clears Click Therapeutics' Motivista, First Treatment For Negative Symptoms Of Schizophrenia — RTTNews